PLAINSBORO, N.J., June 6, 2017 /PRNewswire/ -- Novo Nordisk, a global leader in diabetes care, today announced that data from 60 abstracts will be shared at the upcoming 77th annual Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA, U.S. from June 9-13, 2017. Additionally, three separate ADA-sponsored symposia will highlight data from Tresiba® (insulin degludec injection 100 U/mL, 200 U/mL), Victoza® (liraglutide) and semaglutide.
"There continues to be a need for research and development into new treatment options for people living with diabetes, and our data that will be presented at ADA 2017 will demonstrate how Novo Nordisk is continuing to meet this need," said Todd Hobbs, Vice President and Chief Medical Officer of Novo Nordisk. "Our evolving portfolio reflects our patient-fueled approach to researching and developing a broad range of therapeutic options with data beyond A1C reduction."
Following are key highlights that will be presented at the meeting:
June 10, 11:30 AM – 12:30 PM PT, poster presentation
This press release contains forward-looking statements about investigational products currently in development by Novo Nordisk. As is expected, there is significant risk with drug development and there is no guarantee that future studies will reflect similar results as presented at ADA. For further information about the Novo Nordisk drug pipeline, visit http://www.novonordisk.us.
About Novo Nordisk Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus.
Tresiba®, Xultophy® 100/3.6 and Victoza® are registered trademarks of Novo Nordisk A/S.Novo Nordisk is a registered trademark of Novo Nordisk A/S. All other trademarks, registered or unregistered, are the property of their respective owners.
© 2017 Novo Nordisk All rights reserved. USA17DCP01476 June 2017
Advertisement
"There continues to be a need for research and development into new treatment options for people living with diabetes, and our data that will be presented at ADA 2017 will demonstrate how Novo Nordisk is continuing to meet this need," said Todd Hobbs, Vice President and Chief Medical Officer of Novo Nordisk. "Our evolving portfolio reflects our patient-fueled approach to researching and developing a broad range of therapeutic options with data beyond A1C reduction."
Advertisement
Following are key highlights that will be presented at the meeting:
June 10, 11:30 AM – 12:30 PM PT, poster presentation
- Data from a short-term cost-effectiveness analysis of Xultophy® 100/3.6 (insulin degludec and liraglutide injection, 100 units/mL and 3.6 mg/mL) vs basal-bolus therapy in people with type 2 diabetes in the U.S. (#981-P)
- Results from a real-world assessment on the clinical effectiveness of switching to Tresiba® from another basal insulin in people with type 2 diabetes in the U.S. (#999-P)
- Results from the first completed double-blinded basal insulin trials comparing incidence/occurrence of hypoglycemia across hypoglycemia definitions vs. insulin glargine U100 in the SWITCH 1 and 2 trial (#974-P)
- Phase 3b results from the DUAL VII clinical trial comparing the efficacy and safety of Xultophy® 100/3.6 vs basal–bolus therapy in people with type 2 diabetes (#136-OR)
- Patient reported outcomes from the DUAL VII trial comparing Xultophy® 100/3.6 vs basal–bolus therapy in people with type 2 diabetes (#124-LB)
- Results from DEVOTE, a cardiovascular outcomes study which investigated the cardiovascular safety of Tresiba® compared to insulin glargine U100 in people with type 2 diabetes at high risk of cardiovascular events
This press release contains forward-looking statements about investigational products currently in development by Novo Nordisk. As is expected, there is significant risk with drug development and there is no guarantee that future studies will reflect similar results as presented at ADA. For further information about the Novo Nordisk drug pipeline, visit http://www.novonordisk.us.
About Novo Nordisk Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus.
Tresiba®, Xultophy® 100/3.6 and Victoza® are registered trademarks of Novo Nordisk A/S.Novo Nordisk is a registered trademark of Novo Nordisk A/S. All other trademarks, registered or unregistered, are the property of their respective owners.
© 2017 Novo Nordisk All rights reserved. USA17DCP01476 June 2017
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novo-nordisk-to-present-60-abstracts-at-77th-annual-american-diabetes-association-scientific-sessions-in-san-diego-ca-300469019.html
SOURCE Novo Nordisk
